Table I.
Characteristics of patient and healthy control samples
| Features | AA* (n = 55) |
Uveitis (n = 34) |
SLE (n = 43) |
SCD (n = 5) |
Healthy control (n = 41) |
||
|---|---|---|---|---|---|---|---|
| Median Age | 29 | 55 | 48 | 50 | 33 | ||
| Sex (M/F) | 33/22 | 11/23 | 5/38 | 2/3 | 21/20 | ||
| Diagnosis | Idiopathic 55 | Sarcoidosis | 8 | Idiopathic | 43 | SS 5 | NA |
| VKH | 9 | ||||||
| Birdshot | 15 | ||||||
| Idiopathic | 2 | ||||||
| Disease activity or sevirity | Severe 55 | Active | 7 | SLEDAI> 3 | 24 | NA | NA |
| Non-Severe 0 | Quiet | 27 | SLEDAI≤ 3 | 19 | |||
| Timing at sampling Before therapy | 21 | 9 | 1 | 0 | NA | ||
| After therapy | 34 | 25 | 42 | 5 | |||
| Therapy | ATG+CsA+TPO-RA 55 | PSL | 11 | PSL | 33 | Transfusion Program 4 | NA |
| MMF | 14 | HCQ | 33 | Transfusion + HU 1 | |||
| CsA | 4 | MMF | 6 | ||||
| MTX | 6 | AZA | 9 | ||||
| Anti-TNF | 6 | MTX | 10 | ||||
AA, aplastic anemia; SLE, systemic lupus erythematosus; SCD, sickle cell disease; M, male; F, female; NA, not applicable; VKH, Vogt-Koyanagi-Harada disease; SS, sickle cell anemia; SLEDAI, systemic lupus erythematosus disease activity index, IST, immunosuppressive therapy; ATG, anti-thymocyte globulins; CsA, cyclosporine; TPO-RA, thrombopoietin receptor agonist; PSL, prednisolone; MMF, mycophenolate mofetil; MTX, methotrexate; HCQ, hydroxychloroquine; AZA, azathioprine; HU, hydroxyurea.
*
As serial samples before and after IST were collected from 13 patients (including 3 patients from 3 different time points), the actual patient number is 39.